These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31222454)

  • 1. Septicemic listeriosis during adalimumab- and golimumab-based treatment for ulcerative colitis: case presentation and literature review.
    Horigome R; Sato H; Honma T; Terai S
    Clin J Gastroenterol; 2020 Feb; 13(1):22-25. PubMed ID: 31222454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab for the treatment of ulcerative colitis.
    Flamant M; Paul S; Roblin X
    Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature.
    Abreu C; Magro F; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Mar; 7(2):175-82. PubMed ID: 22626505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Listeria monocytogenes sepsis in ulcerative colitis.
    Kassalik M; Fry LC; Didowacz-Grollmann A; Mousalli S; Mönkemüller K
    Endoscopy; 2012; 44 Suppl 2 UCTN():E219-20. PubMed ID: 22622754
    [No Abstract]   [Full Text] [Related]  

  • 9. Golimumab in inflammatory bowel diseases: present and future scenarios.
    Dragoni G; Le Grazie M; Orlandini B; Rogai F
    Clin J Gastroenterol; 2019 Feb; 12(1):1-9. PubMed ID: 30206776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-colonoscopic Listeria septicemia in ulcerative colitis during immunosuppressive therapy.
    Minami M; Hasegawa T; Ando T; Maeda O; Ohkura T; Ohta M; Goto H
    Intern Med; 2007; 46(24):2023-7. PubMed ID: 18084128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
    Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
    Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Listeria monocytogenes and its relationship with non-biological therapy in inflammatory bowel disease].
    Ontanilla Clavijo G; Trigo Salado C; Leo Carnerero E; de la Cruz Ramírez MD; Araujo Míguez Á; Herrera Justiniano JM; Márquez Galán JL
    Gastroenterol Hepatol; 2015; 38(7):442-3. PubMed ID: 25138387
    [No Abstract]   [Full Text] [Related]  

  • 14. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases.
    Alvisi P; Dipasquale V; Barabino A; Martellossi S; Miele E; Lionetti P; Lombardi G; Cucchiara S; Torre G; Romano C
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):957-961. PubMed ID: 31490707
    [No Abstract]   [Full Text] [Related]  

  • 18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of ulcerative colitis.
    Blonski W; Buchner AM; Lichtenstein GR
    Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab in ulcerative colitis: hypes and hopes.
    Fiorino G; Peyrin-Biroulet L; Repici A; Malesci A; Danese S
    Expert Opin Biol Ther; 2011 Jan; 11(1):109-16. PubMed ID: 21133817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.